Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Last trade$5.60
Day change+$0.6901 (+14.05%)
Day range$4.92 – $5.81
Volume9,968
Market cap$42M
OpenXASE
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$42.42M
Price / earnings
26.28×
Price / book
4.19×
Price / sales
1,116.38×
EV / sales
1,115.83×
EV / EBITDA
-11.59×
Profitability
Earnings per share
$0.19
Return on assets
9.83%
Return on equity
15.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.04×
Quick ratio
0.02×
Cash ratio
0.01×
Cash flow
Price / cash flow
365.71×
Price / free cash flow
365.71×
Free cash flow
$116K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IBO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$21K
$3K
$7K
$7K
$18K
$7K
$0
$0
Cost of revenue
$6K
$19K
$0
$422K
$1K
$19K
$0
$0
Gross profit
$15K
-$16K
$7K
-$415K
$17K
-$12K
$0
$0
Selling, general and administrative
$252K
$259K
$1.88M
$257K
$497K
$658K
$490K
$573K
Research and development
$35K
$76K
$46K
$110K
$52K
$75K
$103K
-$108K
Total operating expenses
$663K
$686K
$2.3M
$743K
$965K
$1.14M
$1.01M
$26.23M
Operating income
-$648K
-$702K
-$2.29M
-$1.16M
-$948K
-$1.15M
-$1.01M
-$26.23M
Interest expense
$0
$0
$0
$0
-$262K
-$260K
-$271K
-$270K
Income before taxes
-$644K
-$700K
-$2.28M
$2.66M
-$1.48M
-$14.35M
-$1.28M
-$27.1M
Income taxes
$0
$0
$0
-$2.58M
$0
$0
$0
$33K
Net income
-$644K
-$700K
-$2.28M
$5.24M
-$1.48M
-$14.35M
-$1.28M
-$27.13M
Net income attributable to common shareholders
-$645K
-$699K
-$2.29M
$5.25M
-$1.47M
-$14.35M
-$1.27M
-$27.11M
EBITDA
-$364K
-$418K
-$2M
-$872K
-$660K
-$865K
-$727K
-$596K
Basic earnings per share
-$0.08
-$0.13
-$0.25
$0.74
-$1.52
-$14.89
-$1.39
-$29.68
Diluted earnings per share
-$0.08
-$0.13
-$0.25
$0.74
-$1.52
-$14.89
-$1.39
—
Recent news
Company coverage with links to the original publishers.
ImPact Biotech announced positive Phase 1 results for Padeliporfin VTP in locally advanced pancreatic cancer, with 75% of 12 treated patients undergoing or scheduled for surgical resection. Seven patients achieved successful resection, with over 55% achieving R0 resections (negative margins). The therapy demonstrated a favorable safety profile across escalating light-dose cohorts, supporting advancement to Phase 1 Part B and regulatory discussions.
Impact Biomedical Inc (NYSE: IBO) announced a 1 for 12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Limited. The merger exchange ratio was corrected to 1 share of Zoar for every 1 share of Impact stock (post-split). Upon completion, the combined entity will focus on developing and supplying Active Pharmaceutical Ingredients for special therapeutic areas.
ImPact Biotech announced updated clinical trial data for Padeliporfin VTP, a vascular-targeted photodynamic therapy. In the Phase 1 LA-PDAC trial, 71% of patients (5/7) achieved successful surgical resection with a well-tolerated safety profile. The Phase 3 ENLIGHTED trial in LG-UTUC showed 70% complete response rates with 85.7% of patients sustaining responses for at least 12 months. The company plans to submit an NDA for LG-UTUC in 2027 and is exploring potential accelerated registrational pathways for LA-PDAC.
ImPact Biotech announced updated Phase 3 ENLIGHTED trial results for Padeliporfin VTP in low-grade upper tract urothelial cancer, showing 70% complete response rate in 72 evaluable patients and 85.7% durability at 12 months. The treatment demonstrated a consistent safety profile with mostly mild to moderate adverse events. Topline data expected later in 2026 with regulatory submission planned for 2027.
Impact BioMedical Inc. (NYSE American: IBO) received a 'going concern' qualification in its 2025 10-K audit opinion from Grassi & Co., CPAs, indicating substantial doubt about the company's ability to continue operations. Despite this financial concern, the company continues pursuing a strategic merger with Dr. Ashley's Ltd., projected to close by July 1, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.